JP Patent

JP7478894B1 — 痒みの予防又は改善剤

Assigned to Kao Corp · Expires 2024-05-07 · 2y expired

What this patent protects

【課題】Ｃ３ａ受容体シグナル伝達経路を阻害することにより、痒みの予防又は改善に有用な新たな素材の提供。【解決手段】オザニモド、その薬学的に許容される塩、又はそのプロドラッグを有効成分とするＣ３ａ受容体拮抗剤。【選択図】なし

USPTO Abstract

【課題】Ｃ３ａ受容体シグナル伝達経路を阻害することにより、痒みの予防又は改善に有用な新たな素材の提供。【解決手段】オザニモド、その薬学的に許容される塩、又はそのプロドラッグを有効成分とするＣ３ａ受容体拮抗剤。【選択図】なし

Drugs covered by this patent

ozanimod-hydrochloride (OZANIMOD HYDROCHLORIDE)

Patent Metadata

Patent number: JP7478894B1
Jurisdiction: JP
Classification: —
Expires: 2024-05-07
Drug substance claim: No
Drug product claim: No
Assignee: Kao Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.